Apogee Therapeutics Inc —— 财务报表 (NASDAQ:APGE) | MetaTrader

展开完整图表

新闻

Spyre Therapeutics Flies On Takeda-Rivaling Ulcerative Colitis Results

Why Delta, Starbucks and these other stocks were just added to a market-beating ‘fresh money’ list

Apogee Therapeutics: 'Strong Buy' As Zumilokibart Progresses To Next Q2 Milestone (APGE)

APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy

Apogee Therapeutics, Inc. (APGE) Discusses 52-Week Phase 2 APEX Data for Zumilokibart in Moderate to Severe Atopic Dermatitis Transcript

Apogee Therapeutics: Two Shots A Year, One Shot At Disruption (NASDAQ:APGE)

Apogee Therapeutics, Inc. (APGE) Discusses 52-Week Phase 2 APEX Data for Zumilokibart in Moderate to Severe Atopic Dermatitis - Slideshow (NASDAQ:APGE) 2026-03-23

How Apogee, Up Almost 20%, Plans To Take On Rival Regeneron's Eczema Drug

Apogee Therapeutics首席执行官Henderson出售150万美元股票

Apogee Therapeutics CEO Henderson sells $1.5 million in stock

加拿大皇家银行资本市场因剂量前景下调Apogee Therapeutics目标价

RBC Capital lowers Apogee Therapeutics stock price target on dosing outlook